Systemic therapy for recurrent endometrial cancer: a review of North American trials.
While early-stage endometrial cancer is highly curable after hysterectomy for the majority of patients afflicted with this disease, recurrent and metastatic endometrial cancer continues to pose a significant challenge. The median survival of women with advanced or recurrent uterine cancer on most recent clinical trials is only approximately 1 year. This review will discuss the developments of systemic therapy in recurrent endometrial cancer, focusing on North American trials, in particular those documenting recent progress in new drug developments, as well as the future of individualized treatment regimens.
Dellinger
Thanh H
TH
Division of Gynecologic Oncology, Chao Family Comprehensive Cancer Center, University of California, Irvine Medical Center, Building 56, Suite 260, 101 The City Drive South, Orange County, CA 92868-3298, USA. tdelling@uci.edu
Monk
Bradley J
BJ
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant / Q000379:methods*; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D016889:Endometrial Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D005260:Female; D006801:Humans; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D009656:North America / Q000453:epidemiology; D015996:Survival Rate
D000970:Antineoplastic Agents